The oral health status of patients on oral bisphosphonates for osteoporosis
Authors:
- 27 November 2008
- journal article
- Published by Wiley in Australian Dental Journal
- Vol. 53 (4) , 354-357
Abstract
Background: The oral health status of patients on bisphosphonates is the key to the patient’s ongoing health and well‐being. If they are orally healthy, invasive bone procedures, particularly extractions can be avoided, then the risk of osteonecrosis of the jaws (ONJ) is low.Methods: The records of 49 consecutive patients on oral bisphosphonates, referred to the Oral and Maxillofacial Surgery Unit (OMSU) for an oral health check and probable extractions, were retrospectively reviewed. The DMFT, periodontal and pathologic state were calculated from the OPG radiographs. An age and gender matched control group, from patients referred to the OMSU but who were not on oral bisphosphonates, were similarly assessed. Community data were also obtained.Results: The DMFT score for the oral bisphosphonate group was 29: Decayed 3, Missing 10, Filled 16. The control group DMFT score was 24: Decayed 5, Missing 11, Filled 8. Both groups had advanced periodontal disease (over 95 per cent) and were medically compromised (over 90 per cent). The DMFT for general community data for age matched government pensioners was 19.1: Decayed 0.8, Missing 10.4, Filled 7.9. With severe periodontal disease 23 per cent. Thus, the oral health of the oral bisphosphonate group was similar to the control group and both had more decayed teeth and periodontal disease than community values.Conclusions: This study confirms that one cannot assume that a patient on an oral bisphosphonate for osteoporosis has a healthy mouth. It supports the view that all patients on bisphosphonates need to be seen by a dentist either before or soon after commencement of bisphosphonate therapy.Keywords
This publication has 9 references indexed in Scilit:
- Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in AustraliaJournal of Oral and Maxillofacial Surgery, 2007
- Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapyJournal of Clinical Oncology, 2006
- The dental implications of bisphosphonates and bone diseaseAustralian Dental Journal, 2005
- Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and TreatmentJournal of Oral and Maxillofacial Surgery, 2005
- Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 casesJournal of Oral and Maxillofacial Surgery, 2004
- Bisphosphanates and Oral Cavity Avascular Bone NecrosisJournal of Clinical Oncology, 2003
- Osteonecrosis of the jaws associated with cancer chemotherapyJournal of Oral and Maxillofacial Surgery, 2003
- Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemicJournal of Oral and Maxillofacial Surgery, 2003
- Oral Health and Heart DiseasePrimary Dental Care, 2002